Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?

Bimekizumab is the fourth biologic inhibiting interleukin
(IL)-17 that has been approved for the treatment of plaquetype psoriasis in Europe.
Do we need it?



Use and reproduction:

CC BY-NC 4.0

Please note that individual components of the publication may be subject to other licensing or copyright conditions.


Citation style:
Could not load citation form.